309735-80-6

Basic information

• Product Name: 1-Piperidinecarboxylic acid, 3-[[(1-oxopropyl)phenylamino]methyl]-, 1,1-dimethylethyl ester
• CAS NO: 309735-80-6
• Molecular Formula: C20H30N2O3
• Molecular Weight: 346.47
• Mol File: 309735-80-6.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1-Piperidinecarboxylic acid, 3-[[(1-oxopropyl)phenylamino]methyl]-, 1,1-dimethylethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Piperidinecarboxylic acid, 3-[[(1-oxopropyl)phenylamino]methyl]-, 1,1-dimethylethyl ester(309735-80-6)
• EPA Substance Registry System: 1-Piperidinecarboxylic acid, 3-[[(1-oxopropyl)phenylamino]methyl]-, 1,1-dimethylethyl ester(309735-80-6)

Safety Data

• Hazardous Substances Data: 309735-80-6(Hazardous Substances Data)

Upstream product

• 309747-96-4 3-{[(2-fluorophenyl)propionylamino]methyl} piperidine-1-carboxylic acid tert-butyl ester 
• 309735-44-2 3-phenylaminomethyl-piperidine-1-carboxylic acid tert-butyl ester 
• 79-03-8 propionyl chloride 

Downstream Products

• 309744-19-2 N-(1-Phenethyl-piperidin-3-ylmethyl)-N-phenyl-propionamide 
• 309744-25-0 N-[1-(Pyridin-3-ylmethyl)-piperidin-3-ylmethyl ]-N-phenyl-propionamide 
• 309746-29-0 N-Phenyl-N-[1-(4-Phenylbutyl)piperidin-3-ylmethyl]propionamide 
• 309744-23-8 N-[1-(4-Methoxybenzyl)-piperidin-3-ylmethyl]-N-phenyl-propionamide 

Relevant articles and documents

Heterocyclic analgesic compounds and methods of use thereof

One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various cellular receptors, including opiate receptors, other G-protein-coupled receptors, and ion channels. An additional aspect of the present invention relates to the use of the novel heterocyclic compounds as analgesics.

Heterocyclic analgesic compounds and methods of use thereof

One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various cellular receptors, including opiate receptors, other G-protein-coupled receptors, and ion channels. An additional aspect of the present invention relates to the use of the novel heterocyclic compounds as analgesics.